BRKR · Bruker Corporation Common Stock
View on chartInsiders & Stakes
No transactions found.
Transaction History
No transactions found.
No transactions found.
No transactions found.
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Bruker Unveils Proteomics Tools, Analysts Lift Targets Amid Competition
Bruker announced new timsUltra AIP and timsOmni workflows that enhance functional proteomics for drug discovery and disease biology. Analysts at Guggenheim and Leerink Partners raised their price targets to $72 and $80, respectively, reflecting confidence in the company’s growth. QIAGEN’s recent FDA‑cleared panel expansion adds competitive pressure in the diagnostics market, where Bruker also operates.
Bruker Unveils Proteomics Tools, Analysts Lift Targets Amid Competition. Bruker announced new timsUltra AIP and timsOmni workflows that enhance functional proteomics for drug discovery and disease biology. Analysts at Guggenheim and Leerink Partners raised their price targets to $72 and $80, respectively, reflecting confidence in the company’s growth. QIAGEN’s recent FDA‑cleared panel expansion adds competitive pressure in the diagnostics market, where Bruker also operates.